Relationship of Diabetes and Heart Disease
Adapted from Cardiac benefits in Diabetes therapy: comparing SGLT2 inhibitors and GLP-1 Agonists
By Samuel Grossman, BS Pharm, PharmD, CDE, FAADE

Kaplan–Meier Estimates of the Probability of Death from Coronary Heart Disease in 1059 Subjects with Type 2 Diabetes and 1378 Nondiabetic Subjects with and without Prior Myocardial Infarction.

Reference(s):